Using PROMIS-29 to determine symptom burdens in the context of the Type 1 and 2 systemic lupus erythematosus (SLE) model: a cross sectional study
Abstract Objective To account for heterogeneity in systemic lupus erythematosus (SLE) and bridge discrepancies between patient- and physician-perceived SLE activity, we developed the Type 1 and 2 SLE model. We examined PROMIS-29 scores, a composite patient-reported outcome (PRO) measure, through the...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SpringerOpen
2023-12-01
|
| Series: | Journal of Patient-Reported Outcomes |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s41687-023-00678-5 |
| _version_ | 1797376974790852608 |
|---|---|
| author | Kai Sun Amanda M. Eudy Nathaniel Harris David S. Pisetsky Lisa G. Criscione-Schreiber Rebecca E. Sadun Jayanth Doss Megan E. B. Clowse Jennifer L. Rogers |
| author_facet | Kai Sun Amanda M. Eudy Nathaniel Harris David S. Pisetsky Lisa G. Criscione-Schreiber Rebecca E. Sadun Jayanth Doss Megan E. B. Clowse Jennifer L. Rogers |
| author_sort | Kai Sun |
| collection | DOAJ |
| description | Abstract Objective To account for heterogeneity in systemic lupus erythematosus (SLE) and bridge discrepancies between patient- and physician-perceived SLE activity, we developed the Type 1 and 2 SLE model. We examined PROMIS-29 scores, a composite patient-reported outcome (PRO) measure, through the lens of the model. Methods Patients completed PROMIS-29 and the polysymptomatic distress scale (PSD). Rheumatologists completed the SLE disease activity index (SLEDAI), and physician’s global assessments (PGAs) for Type 1 and 2 SLE. We defined Type 1 SLE using SLEDAI, Type 1 PGA, and active nephritis, and Type 2 SLE using PSD and Type 2 PGA. We compared PROMIS-29 T-scores among Type 1 and 2 SLE groups and explored whether PROMIS-29 can predict Type 1 and 2 SLE activity. Results Compared to the general population, patients with isolated Type 1 SLE reported greater pain and physical dysfunction but less depression and improved social functions; patients with high Type 2 SLE (irrespective of Type 1 activity) reported high levels of pain, fatigue, and social and physical limitations. Patients with minimal Type 1 and 2 SLE had less depression and greater physical functioning with other domains similar to national norms. PROMIS-29 predicted Type 2 but not Type 1 SLE activity. Conclusion PROMIS-29 similarities in patients with high Type 2 SLE, with and without active Type 1 SLE, demonstrate the challenges of using PROs to assess SLE inflammation. In conjunction with the Type 1 and 2 SLE model, however, PROMIS-29 identified distinct symptom patterns, suggesting that the model may help clinicians interpret PROs. |
| first_indexed | 2024-03-08T19:46:18Z |
| format | Article |
| id | doaj.art-62bf77c2e588407993cc3cbdfbb1f1c3 |
| institution | Directory Open Access Journal |
| issn | 2509-8020 |
| language | English |
| last_indexed | 2024-03-08T19:46:18Z |
| publishDate | 2023-12-01 |
| publisher | SpringerOpen |
| record_format | Article |
| series | Journal of Patient-Reported Outcomes |
| spelling | doaj.art-62bf77c2e588407993cc3cbdfbb1f1c32023-12-24T12:20:21ZengSpringerOpenJournal of Patient-Reported Outcomes2509-80202023-12-01711810.1186/s41687-023-00678-5Using PROMIS-29 to determine symptom burdens in the context of the Type 1 and 2 systemic lupus erythematosus (SLE) model: a cross sectional studyKai Sun0Amanda M. Eudy1Nathaniel Harris2David S. Pisetsky3Lisa G. Criscione-Schreiber4Rebecca E. Sadun5Jayanth Doss6Megan E. B. Clowse7Jennifer L. Rogers8Division of Rheumatology and Immunology, Department of Medicine, Duke University School of MedicineDivision of Rheumatology and Immunology, Department of Medicine, Duke University School of MedicineDivision of Rheumatology and Immunology, Department of Medicine, Duke University School of MedicineDivision of Rheumatology and Immunology, Department of Medicine, Duke University School of MedicineDivision of Rheumatology and Immunology, Department of Medicine, Duke University School of MedicineDivision of Rheumatology and Immunology, Department of Medicine, Duke University School of MedicineDivision of Rheumatology and Immunology, Department of Medicine, Duke University School of MedicineDivision of Rheumatology and Immunology, Department of Medicine, Duke University School of MedicineDivision of Rheumatology and Immunology, Department of Medicine, Duke University School of MedicineAbstract Objective To account for heterogeneity in systemic lupus erythematosus (SLE) and bridge discrepancies between patient- and physician-perceived SLE activity, we developed the Type 1 and 2 SLE model. We examined PROMIS-29 scores, a composite patient-reported outcome (PRO) measure, through the lens of the model. Methods Patients completed PROMIS-29 and the polysymptomatic distress scale (PSD). Rheumatologists completed the SLE disease activity index (SLEDAI), and physician’s global assessments (PGAs) for Type 1 and 2 SLE. We defined Type 1 SLE using SLEDAI, Type 1 PGA, and active nephritis, and Type 2 SLE using PSD and Type 2 PGA. We compared PROMIS-29 T-scores among Type 1 and 2 SLE groups and explored whether PROMIS-29 can predict Type 1 and 2 SLE activity. Results Compared to the general population, patients with isolated Type 1 SLE reported greater pain and physical dysfunction but less depression and improved social functions; patients with high Type 2 SLE (irrespective of Type 1 activity) reported high levels of pain, fatigue, and social and physical limitations. Patients with minimal Type 1 and 2 SLE had less depression and greater physical functioning with other domains similar to national norms. PROMIS-29 predicted Type 2 but not Type 1 SLE activity. Conclusion PROMIS-29 similarities in patients with high Type 2 SLE, with and without active Type 1 SLE, demonstrate the challenges of using PROs to assess SLE inflammation. In conjunction with the Type 1 and 2 SLE model, however, PROMIS-29 identified distinct symptom patterns, suggesting that the model may help clinicians interpret PROs.https://doi.org/10.1186/s41687-023-00678-5Systemic lupus erythematosusPatient-reported outcomesHealth-related quality of life |
| spellingShingle | Kai Sun Amanda M. Eudy Nathaniel Harris David S. Pisetsky Lisa G. Criscione-Schreiber Rebecca E. Sadun Jayanth Doss Megan E. B. Clowse Jennifer L. Rogers Using PROMIS-29 to determine symptom burdens in the context of the Type 1 and 2 systemic lupus erythematosus (SLE) model: a cross sectional study Journal of Patient-Reported Outcomes Systemic lupus erythematosus Patient-reported outcomes Health-related quality of life |
| title | Using PROMIS-29 to determine symptom burdens in the context of the Type 1 and 2 systemic lupus erythematosus (SLE) model: a cross sectional study |
| title_full | Using PROMIS-29 to determine symptom burdens in the context of the Type 1 and 2 systemic lupus erythematosus (SLE) model: a cross sectional study |
| title_fullStr | Using PROMIS-29 to determine symptom burdens in the context of the Type 1 and 2 systemic lupus erythematosus (SLE) model: a cross sectional study |
| title_full_unstemmed | Using PROMIS-29 to determine symptom burdens in the context of the Type 1 and 2 systemic lupus erythematosus (SLE) model: a cross sectional study |
| title_short | Using PROMIS-29 to determine symptom burdens in the context of the Type 1 and 2 systemic lupus erythematosus (SLE) model: a cross sectional study |
| title_sort | using promis 29 to determine symptom burdens in the context of the type 1 and 2 systemic lupus erythematosus sle model a cross sectional study |
| topic | Systemic lupus erythematosus Patient-reported outcomes Health-related quality of life |
| url | https://doi.org/10.1186/s41687-023-00678-5 |
| work_keys_str_mv | AT kaisun usingpromis29todeterminesymptomburdensinthecontextofthetype1and2systemiclupuserythematosusslemodelacrosssectionalstudy AT amandameudy usingpromis29todeterminesymptomburdensinthecontextofthetype1and2systemiclupuserythematosusslemodelacrosssectionalstudy AT nathanielharris usingpromis29todeterminesymptomburdensinthecontextofthetype1and2systemiclupuserythematosusslemodelacrosssectionalstudy AT davidspisetsky usingpromis29todeterminesymptomburdensinthecontextofthetype1and2systemiclupuserythematosusslemodelacrosssectionalstudy AT lisagcriscioneschreiber usingpromis29todeterminesymptomburdensinthecontextofthetype1and2systemiclupuserythematosusslemodelacrosssectionalstudy AT rebeccaesadun usingpromis29todeterminesymptomburdensinthecontextofthetype1and2systemiclupuserythematosusslemodelacrosssectionalstudy AT jayanthdoss usingpromis29todeterminesymptomburdensinthecontextofthetype1and2systemiclupuserythematosusslemodelacrosssectionalstudy AT meganebclowse usingpromis29todeterminesymptomburdensinthecontextofthetype1and2systemiclupuserythematosusslemodelacrosssectionalstudy AT jenniferlrogers usingpromis29todeterminesymptomburdensinthecontextofthetype1and2systemiclupuserythematosusslemodelacrosssectionalstudy |